VRNA logo Verona Pharma : VRNA

VRNA

Stock Data

$106.91

Change up

$0.00 (0.00%)

Asset Type

N/A

Exchange

N/A

Currency

N/A

Country

N/A

Sector

N/A

Industry

N/A

Verona Pharma Plc is a London-based biopharmaceutical company focused on creating treatments for respiratory diseases lacking adequate therapies. Its leading product, ensifentrine, is a novel compound with dual action as a bronchodilator and anti-inflammatory agent, currently in Phase 3 trials for conditions like chronic obstructive pulmonary disease, asthma, and cystic fibrosis. Verona Pharma is exploring ensifentrine in various forms, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler, aiming to meet critical healthcare needs.

All Verona Pharma Articles

7 Articles

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.